Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis

Masaki Yoshikawa, Kazufumi Nakamura, Satoshi Nagase, Satoru Sakuragi, Kengo F. Kusano, Hiromi Matsubara, Tohru Ohe

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Angiotensin II type I receptor blocker (ARB) or statin has been reported to be effective in preventing stent restenosis, but little is known about the combined effect on stent restenosis. The objective of this study was to determine the effect of combination therapy with ARB and statin on restenosis rate after coronary stenting and on proliferation and migration of and reactive oxygen species (ROS) production by human coronary artery smooth muscle cells (SMCs) in vitro. Clinical data were collected from 330 consecutive patients who underwent coronary stenting for de novo lesions. Six months after stenting, quantitative coronary angiography was performed. Combined therapy with the ARB and statin significantly inhibited stent restenosis (P <0.05) compared with the effect of the ARB or statin alone. In an in vitro study, platelet-derived growth factor (PDGF)-induced proliferation was significantly inhibited by combined treatment with CV11974, an ARB, and simvastatin (P <0.01), but the inhibitory effect was not significantly greater than that of simvastatin alone. Migration of human coronary artery SMCs was significantly inhibited by the ARB + statin compared with the effect of the ARB or statin alone (P <0.01). PDGF-induced production of ROS was also inhibited significantly by the ARB + statin compared with the effect of the ARB or statin alone (P <0.01). These results indicate that inhibitory effects of combined therapy on PDGF-induced migration of and ROS production by SMCs play an important role in reduction of restenosis rate. Combined treatment with ARB and statin after stenting is useful for preventing stent restenosis.

Original languageEnglish
Pages (from-to)179-186
Number of pages8
JournalJournal of Cardiovascular Pharmacology
Volume53
Issue number2
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Angiotensin II Type 1 Receptor Blockers
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Stents
Platelet-Derived Growth Factor
Smooth Muscle Myocytes
Reactive Oxygen Species
Simvastatin
Therapeutics
Coronary Vessels
Angiotensin I
Angiotensin Receptor Antagonists
Coronary Angiography

Keywords

  • ARB
  • Combined treatment
  • Statin
  • Stent restenosis

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis. / Yoshikawa, Masaki; Nakamura, Kazufumi; Nagase, Satoshi; Sakuragi, Satoru; Kusano, Kengo F.; Matsubara, Hiromi; Ohe, Tohru.

In: Journal of Cardiovascular Pharmacology, Vol. 53, No. 2, 02.2009, p. 179-186.

Research output: Contribution to journalArticle

Yoshikawa, Masaki ; Nakamura, Kazufumi ; Nagase, Satoshi ; Sakuragi, Satoru ; Kusano, Kengo F. ; Matsubara, Hiromi ; Ohe, Tohru. / Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis. In: Journal of Cardiovascular Pharmacology. 2009 ; Vol. 53, No. 2. pp. 179-186.
@article{fded523e91eb44038121621693e55e6d,
title = "Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis",
abstract = "Angiotensin II type I receptor blocker (ARB) or statin has been reported to be effective in preventing stent restenosis, but little is known about the combined effect on stent restenosis. The objective of this study was to determine the effect of combination therapy with ARB and statin on restenosis rate after coronary stenting and on proliferation and migration of and reactive oxygen species (ROS) production by human coronary artery smooth muscle cells (SMCs) in vitro. Clinical data were collected from 330 consecutive patients who underwent coronary stenting for de novo lesions. Six months after stenting, quantitative coronary angiography was performed. Combined therapy with the ARB and statin significantly inhibited stent restenosis (P <0.05) compared with the effect of the ARB or statin alone. In an in vitro study, platelet-derived growth factor (PDGF)-induced proliferation was significantly inhibited by combined treatment with CV11974, an ARB, and simvastatin (P <0.01), but the inhibitory effect was not significantly greater than that of simvastatin alone. Migration of human coronary artery SMCs was significantly inhibited by the ARB + statin compared with the effect of the ARB or statin alone (P <0.01). PDGF-induced production of ROS was also inhibited significantly by the ARB + statin compared with the effect of the ARB or statin alone (P <0.01). These results indicate that inhibitory effects of combined therapy on PDGF-induced migration of and ROS production by SMCs play an important role in reduction of restenosis rate. Combined treatment with ARB and statin after stenting is useful for preventing stent restenosis.",
keywords = "ARB, Combined treatment, Statin, Stent restenosis",
author = "Masaki Yoshikawa and Kazufumi Nakamura and Satoshi Nagase and Satoru Sakuragi and Kusano, {Kengo F.} and Hiromi Matsubara and Tohru Ohe",
year = "2009",
month = "2",
doi = "10.1097/FJC.0b013e318199f30b",
language = "English",
volume = "53",
pages = "179--186",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis

AU - Yoshikawa, Masaki

AU - Nakamura, Kazufumi

AU - Nagase, Satoshi

AU - Sakuragi, Satoru

AU - Kusano, Kengo F.

AU - Matsubara, Hiromi

AU - Ohe, Tohru

PY - 2009/2

Y1 - 2009/2

N2 - Angiotensin II type I receptor blocker (ARB) or statin has been reported to be effective in preventing stent restenosis, but little is known about the combined effect on stent restenosis. The objective of this study was to determine the effect of combination therapy with ARB and statin on restenosis rate after coronary stenting and on proliferation and migration of and reactive oxygen species (ROS) production by human coronary artery smooth muscle cells (SMCs) in vitro. Clinical data were collected from 330 consecutive patients who underwent coronary stenting for de novo lesions. Six months after stenting, quantitative coronary angiography was performed. Combined therapy with the ARB and statin significantly inhibited stent restenosis (P <0.05) compared with the effect of the ARB or statin alone. In an in vitro study, platelet-derived growth factor (PDGF)-induced proliferation was significantly inhibited by combined treatment with CV11974, an ARB, and simvastatin (P <0.01), but the inhibitory effect was not significantly greater than that of simvastatin alone. Migration of human coronary artery SMCs was significantly inhibited by the ARB + statin compared with the effect of the ARB or statin alone (P <0.01). PDGF-induced production of ROS was also inhibited significantly by the ARB + statin compared with the effect of the ARB or statin alone (P <0.01). These results indicate that inhibitory effects of combined therapy on PDGF-induced migration of and ROS production by SMCs play an important role in reduction of restenosis rate. Combined treatment with ARB and statin after stenting is useful for preventing stent restenosis.

AB - Angiotensin II type I receptor blocker (ARB) or statin has been reported to be effective in preventing stent restenosis, but little is known about the combined effect on stent restenosis. The objective of this study was to determine the effect of combination therapy with ARB and statin on restenosis rate after coronary stenting and on proliferation and migration of and reactive oxygen species (ROS) production by human coronary artery smooth muscle cells (SMCs) in vitro. Clinical data were collected from 330 consecutive patients who underwent coronary stenting for de novo lesions. Six months after stenting, quantitative coronary angiography was performed. Combined therapy with the ARB and statin significantly inhibited stent restenosis (P <0.05) compared with the effect of the ARB or statin alone. In an in vitro study, platelet-derived growth factor (PDGF)-induced proliferation was significantly inhibited by combined treatment with CV11974, an ARB, and simvastatin (P <0.01), but the inhibitory effect was not significantly greater than that of simvastatin alone. Migration of human coronary artery SMCs was significantly inhibited by the ARB + statin compared with the effect of the ARB or statin alone (P <0.01). PDGF-induced production of ROS was also inhibited significantly by the ARB + statin compared with the effect of the ARB or statin alone (P <0.01). These results indicate that inhibitory effects of combined therapy on PDGF-induced migration of and ROS production by SMCs play an important role in reduction of restenosis rate. Combined treatment with ARB and statin after stenting is useful for preventing stent restenosis.

KW - ARB

KW - Combined treatment

KW - Statin

KW - Stent restenosis

UR - http://www.scopus.com/inward/record.url?scp=65549096641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549096641&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e318199f30b

DO - 10.1097/FJC.0b013e318199f30b

M3 - Article

VL - 53

SP - 179

EP - 186

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 2

ER -